Author

A. V. Sheahan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

K. L. Morel· 2 shared L. Ellis· 2 shared A. A. Hamid· 1 shared A. D. Choudhury· 1 shared A. Mitrofanova· 1 shared A. Petersen· 1 shared A. S. Kibel· 1 shared A. Sowalsky· 1 shared

Activity by Year

2019-2019 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

K. L. Morel

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintAug 8, 2019

Targeting EZH2 Increases Therapeutic Efficacy of Check-Point Blockade in Models of Prostate Cancer

A. V. Sheahan, K. L. Morel, D. L. Burkhart…·L. Ellis

This study shows that inhibiting EZH2 enhances the effectiveness of PD-1 checkpoint inhibitors in prostate cancer by increasing PD-L1 expression and immune cell infiltration.

DOI 10.1101/730135

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivApr 29, 2019

Targeting RET Kinase in Neuroendocrine Prostate Cancer

H. VanDeusen, J. R. Ramroop, K. L. Morel…·J. M. Drake

The paper identifies RET kinase as a targetable driver in neuroendocrine prostate cancer (NEPC) through phosphoproteomics and pharmacological inhibition studies, showing reduced tumor growth in models.

DOI 10.1158/1541-7786.mcr-19-1245

humanproteomics

𝕏 PostBluesky